Education
About Us
Working with TipRanks
Follow Us
Everest Medicines Ltd. (HK:1952)
:1952
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$35.54 - HK$77.55
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$13.88B
Enterprise ValueHK$11.81B
Total Cash (Recent Filing)HK$1.59B
Total Debt (Recent Filing)HK$708.72M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 26, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding353,577,880
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)3.58
Price to Sales (P/S)20.64
P/FCF Ratio-19.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, double-digit revenue expansion shows strong commercial traction and market adoption of the company’s offerings. Durable top-line growth provides a foundation for future operating leverage and scale, improving the odds of converting incremental revenue into lasting margins as costs normalize.
High Gross MarginA relatively high gross margin implies favorable product-level economics and pricing power. This structural advantage supports long-term profitability once operating expenses are controlled and scale increases, enabling the company to potentially retain a larger share of incremental revenue.
Conservative Balance SheetLow financial leverage and a strong equity-funded asset base reduce refinancing and solvency risk, important for biotech firms with long development cycles. This resilience gives management flexibility to fund R&D or commercial expansion without immediate pressure from debt maturities.
Bears Say
Persistent UnprofitabilityOngoing negative operating and net margins indicate the company has not yet translated revenue growth into sustainable profitability. Over the medium term this compresses shareholder returns and requires clear evidence of margin improvement or structural cost reduction to restore durable earnings power.
Negative Cash GenerationContinued negative operating and free cash flow forces reliance on external financing or partnerships to fund operations. This structural cash shortfall can dilute shareholders or constrain investment in R&D/commercialization unless the company consistently converts revenue growth into positive cash from operations.
High Operating ExpensesA sizable expense base relative to current revenue limits margin recovery even with strong gross profit. Unless management can sustainably lower SG&A or R&D intensity or achieve substantial scale, elevated operating costs will persistently depress net margins and prolong the path to self-sustaining profitability.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$35.54 and its highest was HK$77.55 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$13.88B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 32 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Aug 28, 2025. The company reported -HK$0.871 earnings per share for the quarter, beating the consensus estimate of -HK$1.143 by HK$0.272.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Overvalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is 0.11.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,577,880 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.871 in its last earnings report, beating expectations of -HK$1.143. Following the earnings report the stock price went down -5.572%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
-15.75%
Trailing 12-Months
Asset Growth
-2.87%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Ltd. (1952) is a biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs in Asia. The company operates primarily in the therapeutic areas of oncology, autoimmune diseases, and infectious diseases. Everest Medicines is dedicated to bringing advanced therapies to patients, leveraging strategic partnerships and collaborations to enhance its product pipeline and market reach.
Technical Analysis
InnoCare Pharma Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---